The INHBE Knockout NCI-H1703 Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population derived from the human NCI-H1703 lung squamous cell carcinoma line, engineered for targeted disruption of the INHBE gene. This product provides a heterogeneous pool of edited cells in which the inhibin beta E subunit is functionally ablated, enabling loss-of-function studies without clonal artifacts. As a polyclonal population, it preserves the genetic diversity of the knockout event and avoids biases associated with single-cell-derived clones, making it well-suited for experiments where representation of multiple knockout alleles is analytically advantageous. The knockout was generated using CRISPR/Cas9 ribonucleoproteins designed to disrupt the coding sequence of INHBE, and the resulting cell pool is supplied as a ready-to-use reagent for immediate downstream applications in cancer and signaling research.
The host NCI-H1703 cell line is a widely characterized model of human non-small cell lung cancer, originally established from a squamous cell carcinoma of the lung. These adherent epithelial cells exhibit typical squamous morphology and harbor molecular features relevant to pulmonary carcinogenesis, including alterations in TP53 and other pathways. As a pulmonary epithelial cell line, NCI-H1703 is extensively employed in studies of lung cancer biology, drug response, and metastatic behavior. The cells grow robustly under standard culture conditions and are amenable to a broad array of biochemical, genetic, and pharmacological manipulations, making them a practical platform for interrogating the functional roles of genes such as INHBE in the context of lung squamous cell carcinoma.
INHBE encodes the inhibin beta E chain, a member of the transforming growth factor beta (TGF-??) superfamily. It heterodimerizes with the inhibin alpha chain (INHA) to form inhibin E, which functions as a secreted antagonist of activin signaling. Inhibin E competes with activins for binding to type II activin receptors ACVR2A and ACVR2B, often in complex with the co-receptor betaglycan (TGFBR3), thereby blocking receptor activation and downstream phosphorylation of SMAD2 and SMAD3. Reduced SMAD2/3 phosphorylation attenuates transcriptional responses, including decreased expression of targets such as Cyclin D1 and c-MYC, while also influencing FSH secretion in reproductive tissues. The pathway is further modulated by follistatin (FST), an extracellular activin-binding protein. INHBE expression itself is regulated by TGF-??, SMAD2/3, FOXO1, and cAMP signaling, positioning INHBE within feedback loops that fine-tune TGF-??/activin balance and downstream cellular outcomes.
In the NCI-H1703 lung squamous cell carcinoma background, INHBE is implicated as a potential tumor suppressor through its inhibition of oncogenic activin signaling. Loss of INHBE function may unleash activin-mediated SMAD2/3 phosphorylation and transcriptional programs that promote proliferation, survival, or invasive behavior. By disrupting INHBE in this cellular context, researchers can investigate how the absence of inhibin E affects cell proliferation, migration, and tumorigenicity. The polyclonal knockout population allows assessment of these phenotypes without the confounding effects of clonal selection, providing a more physiologically relevant model of gene loss. Furthermore, because the TGF-?? superfamily plays dual roles in cancer, this tool enables dissection of the specific contribution of the inhibin?Cactivin axis to lung squamous carcinoma pathogenesis.
This polyclonal knockout model supports a range of advanced research applications. Investigators can perform detailed mechanistic studies using Western blotting to confirm INHBE loss and RT-qPCR to quantify transcript levels, while phospho-SMAD2/3 flow cytometry allows single-cell analysis of signaling pathway activation. Functional assays such as MTT-based proliferation, transwell migration/invasion, and xenograft tumor growth in immunocompromised mice are directly applicable for evaluating the consequences of INHBE knockout on tumor cell behavior. The cells also serve as a platform for drug target validation efforts in metabolic syndrome and obesity, where inhibin E plays a role in energy homeostasis, and for screening small molecules that modulate the TGF-??/activin pathway. For further technical details, experimental protocols, or ordering information, please contact Ascent Research.
